Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with DabogratinibPR Newswire•09/09/2026•11:000 ShareWhiz InsightsGenerateNo content available.
